	STUDY PERIOD										
	Enrolment	**Allocation**	**Post-allocation**								**Close-out**
	Screening period		**Treatment period**						**Follow-up period**		
TIMEPOINT	**M-1 ~M0**	**M0**	**M1 ±D7**	**M2 ± D7**	**M3 ±D7**	**M4 ±D7**	**M5 ±D7**	**M6 ±D7**	**M9 ±D7**	**M12 ±D7**	**M18 ±D7**	**M19**
ENROLMENT:											
Eligibility screen	X										
Informed consent	X										
Allocation		X									
INTERVENTIONS:											
Control Arm			←	—	—	—	—	→			
Investigation Arm			←	—	—	—	—	→			
ASSESSMENTS:											
Variables											
Demographic information and medical history	X										
Physical examination	X		X	X	X	X	X	X	X	X	X	
Height	X										
Body Weight	X		X	X	X	X	X	X	X	X	X	
Acid-resistant staining	X		X	X	X[a]		X	X	X[d]	X[d]	X[d]	
Culture of Mycobacterium Tuberculosis	X		X	X	X[a]		X	X	X[d]	X[d]	X[d]	
Xpert	X		X	X	X[a]		X[b]	X[c]	X[d]	X[d]	X[d]	
Chest CT	X			X				X	X	X	X	
Blood Routine	X		X	X	X[a]			X				
Urine routine	X			X	X[a]							
HBsAg	X											
HCV-Ab	X											
HIV-Ab	X											
ESR	X		X	X	X[a]			X				
CRP	X		X	X	X[a]			X				
Liver Function	X		X	X	X[a]			X				
Kidney Function	X		X	X	X[a]			X				

Blood Glucose	x										
Glycated Hemoglobin	x										
ECG	x		x	x	x[a]			x			
Adverse Event			x	x	x	x	x	x	x	x	
Check of Compliance			x	x	x	x	x	x			
Record of combined medication	x		x	x	x	x	x	x	x	x	
Evaluation of Efficacy								x		x	
Review of CRF								x		x	
Primary oucomes											
The rate of adverse outcomes											x
Secondary outcomes											
The rate of Treatment success				x	x		x	x			
The rate of sputum Mtb negative conversion				x	x		x	x			
The time of sputum Mtb negative conversion				x	x		x	x			
Number of Patients With Adverse Events											x

Table 1 The schedule of treatments and data collection.

M-1: One month before the research; M0: The start of the research; M1: The 1st month of the research; M2: The 2nd month of the research; M3: The 3rd month of the research; M4: The 4th month of the research; M5: The 5th month of the research; M6: The 6th month of the research; M9: The 9th month of the research; M12: The 12th month of the research; M18: The 18th month of the research; ±D7: Plus or minus 7 days）

Note:

a: For those who are still bacteria positive at the end of the 2nd month, the intensive period is extended by one month, and the items that need to be checked when the treatment time reaches the end of the 3rd month;

b: Items to be checked for patients with positive sputum smear when the treatment time reaches the end of the 5th month;

c: Items to be checked for patients with negative sputum smear at the end of the 5th month and positive sputum smear at the end of the 6th month of the treatment time.

d: Items to be checked for patients with symptoms and/or signs of active tuberculosis after discontinuation of the

drug, and chest CT suggesting relapse.

During the follow-up period, the researcher may increase the number of the above-mentioned examination items as appropriate according to the patients' condition.